Veerox

Quick links to important sections

Veerox

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Veerox

Property Description
Active ingredient Roxithromycin
Form Tablets, Film-coated tablets, Oral suspension
Pharmacological class Macrolide antibiotic
Origin Semi-synthetic (Erythromycin derivative)
Common Use Anti-infective agent (systemic use)

What Type of Medicine is Veerox? (Identity and Classification)

Veerox is strictly a prescription-only medicine containing the single active ingredient Roxithromycin. This drug is classified as a Macrolide antibiotic, a clinically recognized group of anti-infective agents used for the systemic treatment of susceptible bacterial infections. The drug's primary function is antimicrobial, meaning it acts against microorganisms to manage infectious conditions. The medication is primarily supplied for oral intake, available in common pharmaceutical presentations such as tablets, film-coated tablets, and sometimes as an oral suspension. The Macrolide classification indicates that it provides an essential therapeutic option, often employed when managing bacterial infections that may show reduced susceptibility to other classes of common antibacterial agents.


Composition and Origin: Is Roxithromycin a Natural Derivative? (Composition and Origin)

The core substance, Roxithromycin, is a semi-synthetic antibiotic and a chemical Erythromycin derivative. This means the compound's structure is modified in a laboratory from the natural macrolide base to achieve specific benefits, such as enhanced stability and improved absorption within the body. This semi-synthetic origin differentiates it from older, naturally derived antibiotics. As a single-ingredient product, Veerox ensures that only Roxithromycin is combined with the necessary pharmaceutical preparation base required to create the final oral dosage forms suitable for widespread systemic use.


The General Purpose of Macrolide Antibiotics (High-Level Benefit)

The overall objective of Roxithromycin is to manage and control imbalances caused by susceptible bacterial infections throughout the body. It operates through a bacteriostatic action, which is its ability to prevent the bacteria from multiplying and spreading. This fundamental property of macrolides is crucial. By interfering with the bacteria’s necessary processes for growth, this anti-infective agent critically reduces the overall bacterial load, allowing the body's natural immune system to successfully clear the infection and restore microbial balance, which is the general therapeutic goal of this systemic treatment.

Regulatory References

  1. Macrolides Mechanism of Action (NCBI/NIH)

What side effects are possible with Veerox?

Possible Side Effects and Safety Information for Veerox

Veerox (fezolinetant) is associated with a risk of rare but serious liver injury, a safety concern highlighted in official regulatory labeling. This risk is acknowledged with a Boxed Warning, the most prominent safety alert designated by the U.S. Food and Drug Administration (FDA).

Key Safety Concerns

Adverse Reaction Category Details and Classification
Hepatobiliary Disorders Includes elevated liver blood test values and rare but serious liver injury (hepatotoxicity). The serious nature of this reaction required a Boxed Warning update.
Systemic Symptoms Signs and symptoms suggestive of liver problems, such as unusual fatigue, nausea, vomiting, dark urine, light-colored stools, unusual itching, or yellowing of the skin or eyes (jaundice).

Safety Restrictions and Monitoring

Official prescribing information mandates strict monitoring requirements to identify potential liver injury as early as possible:

  • Liver Blood Testing: Hepatic laboratory tests are required before initiating treatment. Monitoring must continue at regular intervals throughout the first nine months of therapy: monthly for the first three months, and then again at months six and nine.
  • Discontinuation Criteria: Treatment must be immediately stopped if signs or symptoms of liver injury develop, or if specific laboratory thresholds are met (e.g., transaminase levels exceeding five times the Upper Limit of Normal, or three times the ULN when accompanied by elevated total bilirubin). Postmarketing reports indicate that liver injury has been documented within approximately 40 days of starting treatment.

The regulatory safety structure focuses heavily on this hepatic risk through mandatory monitoring and defined discontinuation parameters, which govern the safe use of this medication.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Veerox (Roxithromycin) is officially documented to primarily present with prominent gastrointestinal disturbances, including nausea, vomiting, epigastric pain, and diarrhea.

The principal life-threatening risk following an overdose is the potential for severe cardiovascular effects. Regulatory documentation emphasizes the potential for QT interval prolongation and serious ventricular arrhythmias, such as Torsades de Pointes and ventricular tachycardia, which require urgent clinical attention.

Emergency Actions Required

  • Seek immediate medical attention upon any suspected overdose or when too many tablets have been taken.
  • The mandated action is to immediately contact your doctor or a poison control center, or proceed directly to the nearest Emergency Department.
  • Urgent medical help is required even if there are no immediate signs of discomfort or poisoning, due to the potential for delayed cardiac complications.

Management and Monitoring

As no specific antidote is known, the official management protocol relies on necessary supportive and procedural measures. These include required symptomatic treatment and supportive care, alongside procedures such as gastric lavage to remove unabsorbed medication. Due to the inherent cardiac risk, ECG monitoring should be performed, and continuous hospital observation may be required to address potential ventricular arrhythmias.

Therapeutic Uses of Veerox

What Veerox Treats: Main Uses and Benefits

This medication is primarily used to manage mild to moderately severe bacterial infections across several major therapeutic domains. It provides supportive therapeutic benefit by addressing the symptoms associated with the infection itself. Its therapeutic relevance is aligned with treating infections of the upper and lower respiratory tracts, skin, and soft tissues.

It is commonly used to help manage groups of symptoms related to acute infections, such as pharyngitis, tonsillitis, and community-acquired pneumonia (CAP), alongside skin and soft tissue infections like cellulitis and impetigo. It is commonly used to offer symptomatic relief that helps patients cope more steadily with difficult episodes.

Veerox is particularly relevant in clinical settings marked by infections caused by atypical bacteria (Mycoplasma or Chlamydia) or when a patient has a documented penicillin allergy and requires an alternative systemic antibacterial option. This provides a supportive treatment path, assisting with maintaining functional stability when typical first-line antibiotics are unavailable.

“This medication is applied across domains where additional symptomatic support is needed, helping ease the overall burden of symptoms that may become intense or disruptive.”

Quick Fact: Relief for Fever and Sore Throat

Regulatory References

  1. Medsafe New Zealand Data Sheet for Roxithromycin

Eligibility and Restrictions for Use

Veerox (Roxithromycin) is an antibiotic whose use is defined by specific official eligibility and non-eligibility rules.

Populations Strictly Prohibited (Contraindicated)

Veerox must not be used by individuals who have a known allergy or hypersensitivity to roxithromycin or any other macrolide antibiotic (e.g., erythromycin, azithromycin). It is also contraindicated for patients taking certain interacting medications, including vasoconstrictive ergot alkaloids (like ergotamine or dihydroergotamine) or specific drugs associated with cardiac rhythm issues, such as cisapride, pimozide, astemizole, or terfenadine.

Eligibility Requiring Special Consideration

Use is not recommended in patients with severe hepatic (liver) impairment (e.g., cirrhosis). For patients with mild to moderate liver impairment, caution and potential dose reduction are necessary. The medicine is generally not recommended for children under the age of 40 kg or those under six years, although age-specific formulations may be available. Use during pregnancy and lactation should only occur after careful medical consultation, as the drug passes into breast milk and is generally advised against as a precaution. Caution is also warranted in patients with uncorrected electrolyte imbalances or a pre-existing condition that may prolong the QT interval on an ECG.

What should I know about interactions with other medicines?

Veerox Interactions with other medicines and products

The regulatory profile for Roxithromycin (Veerox) is structured around official prohibitions and pharmacokinetic changes that affect co-administered substances. This information is strictly derived from government drug labels and prescribing information.

Interaction Scope

Medicinal product categories with documented interactions: Macrolide-class sensitive agents, Vitamin K Antagonists, P-gp Substrates, and CYP3A4 Substrates.

Specific interacting medicines (if explicitly listed): Ergotamine, Cisapride, Astemizole, Pimozide, Warfarin, Digoxin, Midazolam, and Theophylline.

Mechanistic basis of interactions (only if stated in label): Pharmacokinetic effects (e.g., weak inhibitor of CYP3A4 and P-glycoprotein inhibition) and Pharmacodynamic effects (e.g., additive QT prolongation).

Timing-based interaction rules (if applicable): Administration must be separated from food (15 minutes before or 3 hours after a meal) due to the documented decrease in oral absorption. Separation from Antacids (2 hours before or after) is also advised by regulatory authorities.

Population-specific interaction notes (if applicable): In cases of severe hepatic impairment, the drug's serum half-life is increased, which requires regulatory consideration of the dose to manage interaction risk.

Interaction Classifications (High-Level)

Interaction severity classification (as defined in official documents): Contraindicated Combinations (e.g., Ergot Alkaloids, Cisapride) and Use-With-Caution Combinations requiring monitoring for increased drug exposure (e.g., Warfarin, Digoxin).

Regulatory basis (EMA / FDA / etc.): Official prescribing information (SmPC equivalents, national drug authority data sheets).

Resulting Interaction Structure

Official interaction statements:

  • The co-administration of Ergot Alkaloid Derivatives is strictly prohibited due to the risk of severe vasoconstriction and necrosis (ergotism).
  • The use of Cisapride, Astemizole, or Pimozide is prohibited due to the documented risk of QT interval prolongation and cardiac arrhythmias.
  • Concomitant use with Vitamin K Antagonists (e.g., Warfarin) is officially documented to result in an increased International Normalised Ratio (INR).
  • Midazolam exposure is officially documented to increase by 47% when co-administered.
  • Co-administration with Class IA and III Antiarrhythmic Agents carries a heightened, officially documented risk of QT prolongation.

Connection to the overall interaction profile: Regulatory documents define the product’s interaction structure through absolute prohibitions for agents causing cardiotoxicity or severe vasoconstriction, and pharmacokinetic findings that increase the exposure of co-administered substances.

Mechanism of Action

Veerox's mechanism of action is distinctly two-fold, involving both direct microbial interference and complex modulation of host physiological responses.

Inhibition of Bacterial Protein Synthesis

The core function of Roxithromycin is to act as a specific inhibitor of the bacterial cell's protein-making machinery. It achieves this by reversibly binding to the 50S ribosomal subunit, specifically the 23S ribosomal RNA component. This molecular attachment physically blocks the nascent peptide exit tunnel, which halts the critical translocation step in protein synthesis. By preventing the construction of proteins essential for survival and reproduction, the drug exerts a bacteriostatic effect, thereby stabilizing the bacterial population, which enables the host immune defenses to process the microorganisms.

️ Modulation of Host Cellular Signaling

Beyond its microbial target, Roxithromycin engages mechanisms that modulate host physiological processes. The molecule influences inflammatory signaling by affecting key transcription factors like NF-κB, leading to the suppression of pro-inflammatory mediators such as IL-8 and IL-1β. This secondary effect contributes to limiting the systemic impact of the physiological inflammatory response associated with microbial challenge. The drug also affects respiratory cells, supporting the regulation of mucus hypersecretion and leading to a modulated state within the targeted physiological pathways, ultimately contributing to the systemic restoration of physiological balance.

Dosage and Administration Information

Official Administration Guidelines

Veerox, which contains the active ingredient Roxithromycin, is administered exclusively by the oral route as film-coated tablets or an oral suspension. The medication is supplied in standard strengths, including 150 mg and 300 mg tablets. The most common adult dosing regimen specifies a total daily intake of 300 mg. This total is typically achieved by taking 150 mg twice daily (every 12 hours) or, alternatively, 300 mg once daily.

To ensure optimal systemic absorption, Veerox must be taken on an empty stomach. This means the dose should be taken at least 15 minutes before any food or significantly after a meal (e.g., three hours or more). Tablets must be swallowed whole with a drink and should not be crushed.

The duration of use is typically constrained to a limited course, generally lasting 5 to 10 days, depending on the specific infection being addressed. However, certain protocols, such as those for streptococcal throat infections, mandate a minimum duration of ten days.

Specific dose adjustments are required for certain patient groups. For individuals with severe hepatic impairment, the labeled dose must be reduced to 150 mg once daily. Dosing for children weighing less than 40 kg is determined by body weight, typically 5 to 8 mg/kg/day in two divided doses. If a dose is missed, patients are instructed not to take a double dose; instead, they should skip the missed dose if it is near the time for the next scheduled dose.

Recent Clinical Evidence

Research evidence / Overview of studies for Veerox


Evidence for Use in Acute Respiratory Tract Infections

Roxithromycin was studied in research exploring contexts involving acute infections of the upper and lower respiratory tract, such as pharyngitis, tonsillitis, acute bronchitis, and community-acquired pneumonia. The research base primarily consists of short-term Randomized Controlled Trials (RCTs) and comparative clinical studies where Roxithromycin was evaluated in patients with mild to moderate conditions characterized by fluctuating or episodic manifestations. These studies used in research exploring how symptoms change over time by measuring the evolution of signs and symptoms related to the infection, as well as the clearance of the specific bacteria causing the infection.

Studies monitored outcomes related to physical discomfort and systemic or functional imbalance over the course of the treatment. Studies reported measurements detailing how symptoms evolved in the observed populations during the study period, though findings in comparative trials can show variability. What remains uncertain is the long-term persistence of the observed symptom patterns after the treatment has concluded, as follow-up durations were limited.


Evidence for Use in Skin and Soft Tissue Infections

Clinical research also explored its use in clinical contexts involving skin and soft tissue infections (SSTIs), including conditions like cellulitis and impetigo. This body of evidence includes historical comparative clinical trials that research examined alongside other commonly prescribed antibiotics for SSTIs. The research examined outcomes related to physical discomfort at the site of infection, such as tracking changes in lesion size and inflammation levels.

Evidence is limited regarding the performance of Roxithromycin in modern comparative trials involving the newest treatments for SSTIs. Since many of the core studies are older, there is limited information available for its performance against specific, recently emerged resistant bacteria that may be prevalent today.


Research into Non-Antibacterial Applications

Macrolide antibiotics as a class was studied in research exploring non-antibacterial activity, and some smaller randomized, controlled trials have explored Roxithromycin in this context. The research examined outcomes linked to inflammatory or irritative states and the rate at which patients reported episodic or acute changes (exacerbations). Findings were mixed regarding objective measures like standard lung function tests, which often appears to show minimal or no significant changes. Data specific to Roxithromycin for this long-term use is limited.


What is Still Uncertain About Veerox's Research

While a significant amount of research contributes to the broader evidence landscape for Roxithromycin, the research also highlights several areas where certainty remains low or data are insufficient. Evidence quality varies across studies, particularly when examining Roxithromycin alongside the full spectrum of newer antibiotic alternatives currently available. A key research gap remains the lack of comprehensive data, and long-term outcomes are not fully established following patients over several years.

Key Studies & References

  1. Roxithromycin - FDA Verification Portal (National Regulatory Monograph)
  2. The role of roxithromycin in the treatment of respiratory tract infections: a comprehensive overview (Systematic Review)
  3. Clinical efficacy of roxithromycin in the treatment of adults with upper and lower respiratory tract infection due to Haemophilus influenzae: a meta-analysis of 12 clinical studies
  4. The overall safety of oral roxithromycin in paediatric clinical studies (Clinical Study)
  5. Roxithromycin - Drugs and Lactation Database (LactMed®) - NCBI Bookshelf - NIH

Frequently Asked Questions (FAQ)

Common questions about Veerox (FAQ)


Q: How long does it usually take to notice any change after starting Veerox?

A: Official information indicates that individuals taking Veerox may observe an improvement in their symptoms within a few days of starting the treatment. It is described that the full course should be completed, even if symptoms appear to improve early, to effectively treat the infection.


Q: Is there anything specific I should try to avoid eating or drinking while using Veerox?

A: To ensure the drug is absorbed properly, official administration guidelines state that Veerox must be separated from both food and antacids. Specifically, the dose should be taken at least 15 minutes before any food or two hours before or after taking antacids. This guidance is provided in official documentation.


Q: What if I take another medicine that is known to interact with Veerox?

A: Regulatory documents listing drug interactions are intended for the information of healthcare professionals. Official guidance advises patients to inform their prescriber about all medicines they are currently taking, including over-the-counter products and supplements. This enables a healthcare provider to assess the potential risk and determine the appropriate course of action.


Q: How does alcohol consumption relate to using Veerox?

A: Official patient information often advises individuals to inform their healthcare provider if they consume alcohol. While a specific prohibition may not be listed, alcohol consumption can potentially worsen general side effects that have been reported with Veerox, such as stomach upset or dizziness. Official guidance emphasizes that any questions about alcohol consumption during treatment should be discussed with a healthcare provider.


Q: Does taking Veerox affect the ability to drive or operate machinery?

A: Official patient leaflets for Veerox advise individuals to be aware of how the drug affects them personally before driving or using machinery. This caution is issued because some reported side effects include neurological symptoms like dizziness or vertigo, which are effects that can impact concentration and motor skills.


Q: What are the research conclusions regarding Veerox and its intended use?

A: Clinical trial summaries from regulatory agencies describe the research conducted on Veerox in the context of treating susceptible bacterial infections. These studies explored its use for acute respiratory tract infections and skin/soft tissue infections, focusing on outcomes related to symptom evolution and the clearance of the targeted bacteria within the populations studied.


Q: Are the common side effects of Veerox serious?

A: Official prescribing information documents both common and rare side effects. Common side effects often involve gastrointestinal issues such as nausea, vomiting, diarrhea, or abdominal pain. These effects are typically managed and are not listed among the serious or life-threatening adverse reactions like the rare risk of liver injury, which requires mandatory monitoring.


Q: I heard Veerox can cause X side effect—how often does that happen to people?

A: Official product information, such as the Summary of Product Characteristics (SmPC), classifies side effects by their frequency in study populations. For example, effects like nausea and diarrhea are classified as 'common,' meaning they are seen in a measurable percentage of patients, while others are noted as 'uncommon' or 'rare,' like the serious risk of liver injury.


Q: Are there any known interactions between Veerox and common over-the-counter pain relievers?

A: Official drug labels list specific prescription medications with known contraindications or interactions. While common over-the-counter pain relievers may not be listed directly, the general warning advises patients to inform their healthcare provider about all concomitant medications. This allows the provider to screen for any potential additive effects or pharmacokinetic changes.


Q: Does Veerox interact with birth control pills?

A: Official reviews for this macrolide antibiotic suggest that the drug does not interfere with the efficacy of oral contraceptives, unlike some other antibiotic classes. However, given that individual responses can vary, official patient information advises discussing all current medications, including contraceptives, with a healthcare professional.


Q: What kind of research has been done on the long-term effects of Veerox?

A: Research on the macrolide class of antibiotics has explored long-term, non-antibacterial use in patients with chronic respiratory conditions. However, the core evidence base for Veerox itself is built primarily on studies designed to assess its effectiveness and safety during short-term treatment courses for acute infections.


Q: Is Veerox a drug that I would need to take forever?

A: Veerox is officially approved and dosed for the short-term management of acute bacterial infections. Official administration guidelines detail short treatment courses, typically lasting between 5 and 10 days. The official labeling does not suggest that this medicine is intended for long-term or indefinite use.


Q: Is Veerox considered a highly addictive or controlled substance?

A: According to national drug schedules and official regulatory listings, Veerox (Roxithromycin) is classified strictly as a prescription-only antibiotic. It is not designated or listed as a controlled or highly addictive substance.


Q: Why do some people say they feel tired after taking Veerox?

A: Official documents listing possible side effects include systemic symptoms such as fatigue. These symptoms are part of the known profile of the drug and are reported to occur in some individuals while they are undergoing treatment.


Q: Is it normal to have a slight headache when first starting Veerox?

A: Official prescribing information for Veerox lists headache in the adverse events section. This means that a headache is a recognized side effect that is commonly or less commonly reported by patients when they begin treatment.


Q: What age group is Veerox typically prescribed to?

A: Veerox has standard dosing regimens defined for adults. Official information also includes specific weight-based pediatric dosing for children, typically those weighing over 40 kg or six years of age and older. This indicates that the medicine is primarily used in adult and older pediatric populations.


Q: Are there any official patient guides or leaflets for Veerox I can read online?

A: Yes, regulatory agencies in various countries mandate that Patient Information Leaflets (PILs) or Consumer Medicine Information (CMI) be created for all approved medicines. These official documents are typically available online through the websites of the relevant governmental drug authority.


Q: Is the effect of Veerox permanent, or does it only work while you are taking it?

A: Veerox operates through a bacteriostatic action, meaning its primary role is to stop susceptible bacteria from multiplying while the drug is present in the system. The drug works during the course of treatment to reduce the bacterial load, which then allows the body’s natural immune system to clear the infection and restore balance.


Q: If I have a mild reaction, is that considered a sign of a serious side effect from Veerox?

A: Official safety information for Veerox focuses on identifying specific signs and symptoms of severe reactions, particularly those related to the liver, such as jaundice, unusual fatigue, or specific lab changes. A mild reaction is generally considered separate from these officially defined, serious discontinuation criteria, which indicate the need for immediate medical attention.


Q: What percentage of patients experience the most common side effects of Veerox?

A: Official regulatory documents, such as the SmPC, classify the frequency of common side effects, such as nausea or diarrhea, by defining a percentage range. These official classifications (e.g., 'common' or 'uncommon') are based on the reported incidence seen during clinical trials and post-marketing surveillance.


Q: Are there certain foods that can increase the risk of side effects from Veerox?

A: Official administration guidance is concerned with food affecting the drug's absorption, requiring it to be taken on an empty stomach. No specific foods are listed in regulatory documents as increasing the risk of adverse side effects. The focus is on taking the medicine as directed to maintain stable absorption.


Q: Does Veerox change the effectiveness of supplements like vitamins or herbal remedies?

A: Official interaction sections primarily list interactions with other regulated medications. However, the overarching safety warning advises patients to disclose all concomitant use, which includes herbal remedies and vitamins. This is because interaction information for supplements may not be fully documented and requires assessment by a healthcare provider.


Q: How long after stopping Veerox do the side effects usually go away?

A: The pharmacokinetics section of official information provides the drug's elimination half-life, which is approximately 12 hours. This figure indicates how quickly the drug concentration is reduced in the body by half. Most of the medication is generally cleared from the system within several half-lives after the final dose.


Q: Can Veerox cause any skin reactions?

A: Yes, official adverse events sections document that Veerox can cause skin reactions. These can include signs like a rash or urticaria (hives), and they are categorized by official agencies based on the frequency with which they are reported in patient populations.


Q: What if I am taking Veerox for a different reason than my friend?

A: Regulatory documents state that Veerox is approved for the treatment of susceptible bacterial infections in several different anatomical sites, such as the respiratory tract and skin/soft tissues. Therefore, two people may be taking the same medicine for different, but indicated, sites of infection.

How should Veerox be stored and disposed of?

Storage and Protection Requirements

Veerox (Roxithromycin) tablets must be stored at a temperature not exceeding 30 C (86 F), with some regulatory guidance specifying storage below 25 C (77 F). The product must be protected from both light and moisture and should not be exposed to excessive heat. To maintain stability, the medicine must be kept in its original pack or outer carton, and the container must be kept tightly closed.

Child Safety and Disposal

It is a mandatory requirement to keep this medicine out of the sight and reach of children at all times. Disposal of any unused or expired Veerox must strictly follow local regulations; the product must not be thrown away via household waste or wastewater to prevent environmental contamination. Unused medicine should be returned to a pharmacy or designated collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Veerox found in:

A-Z Index: